Assuring that a stable cell line originates from a single progenitor cell is a fundamental component of the development of protein, cellular and gene therapies. However, monoclonality assurance is often a rate-limiting step in cell line development, leading to project delays and increased risk.
In this webinar, Adam Causer will provide an overview of an end-to-end workflow that not only achieves 99.99% probability of clonality but also digitalizes and automates the process of generating evidence of clonality for IND submissions.
Attendees will gain actionable insights into minimizing ghost well risk using gentle, automated single‑cell deposition, and an overview of how to achieve workflows capable of delivering greater than 99.99% Probability of Clonality when combined with high‑throughput whole‑well imaging – without sacrificing throughput or efficiency through the use of AI‑powered data management and analytics.
Speaker
Adam Causer, Global Product Manager, Solentim Portfolio, Nova Biomedical
Adam Causer is a Global Product Manager for the Solentim Portfolio at Nova Biomedical, which includes an ecosystem of instruments that digitalize and automate CLD workflows. Prior to starting this role, he worked in application sciences at both Scienion and Advanced Instruments, specializing in precision dispensing and single-cell isolation for diagnostic test development and CLD, respectively.
Adam’s early career included being a postdoctoral researcher that oversaw the day-to-day management of Cancer Research UK (CRUK), National Institute for Health Research (NIHR) and university-funded research projects. For these projects, he used a combination of basic science and physiological techniques to investigate the benefits of exercise on health, disease and pharmaceutical treatments. These techniques included cell culture, live cell imaging, flow cytometry, cell killing assays and multiplex protein quantification.
Message PresenterWho Should Attend?
This webinar is of value to:
- Scientists, engineers and lab managers in CLD looking to integrate or expand automation
- Process development staff in biotech companies and CDMOs seeking to improve or internalize cell line workflows
- Professionals driving scalable biologics development who aim to boost productivity and batch‑to‑batch consistency while reducing re‑cloning cycles
- QA/Regulatory and CMC documentation owners building a stronger case for regulatory submissions
- Decision‑makers who want to future‑proof CLD operations through strategic automation and analytics
What You Will Learn
Attendees will gain insights into:
- Practical ways to minimize false positive (ghost well) risk through nanodroplet and whole well brightfield imaging
- Key strategies for validating a workflow with 99.99% Probability of Clonality utilizing fluorescence whole-well imaging
- Understand how AI and data centralization can reduce FTE demands of image analysis by over 50%
Xtalks Partner
Nova Biomedical
Advanced Instruments and Nova Biomedical are now doing business under the same brand, bringing together decades of expertise in analytical instrumentation, R&D, and global customer support. The Solentim® ecosystem is now part of Nova Biomedical’s portfolio, providing best-in-class imaging and single-cell deposition technologies for cell line development workflows and assurance of clonality for regulatory bodies.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account